44 studies find no consistent cardiometabolic harm from hormonal contraceptives

As hypertension, diabetes, and obesity have grown more common among women of reproductive age, the question of whether hormonal contraceptives are safe for women who already have one of these conditions has become more clinically pressing. A systematic review published this month in the International Journal of Women's Health pulls together a decade of research to assess what's actually known [s1].

The design

Following PRISMA 2020 guidelines, researchers searched PubMed, Web of Science, and Scopus for English-language human studies published between 2015 and 2025, including randomized controlled trials, cohort studies, case-control studies, and comparative observational designs [s1]. Because study populations, contraceptive exposures, and outcome measures varied too widely for formal meta-analysis, findings were synthesized descriptively [s1]. Forty-four studies met inclusion criteria [s1].

What it found

Combined estrogen-containing contraceptives were by far the most studied, appearing in 79.5% of included studies (35 of 44), followed by progestin-only methods (18.2%), long-acting reversible contraceptives (18.2%), and mixed hormonal exposures (13.6%) [s1]. Hypertension was the most frequently studied comorbidity, followed by diabetes and obesity [s1]. Coverage of specific outcome types was uneven: lipid and metabolic parameters were reported in 31.8% of studies, blood pressure outcomes in 25.0%, and glycaemic (blood sugar) outcomes in just 15.9% [s1].

The overall conclusion: no consistent short-term cardiometabolic harm was found across the reviewed evidence [s1]. That said, modest adverse changes — increases in systolic blood pressure, triglycerides, and insulin resistance — were identified in selected high-risk subgroups [s1], meaning the reassuring topline finding doesn't apply uniformly to every woman with a relevant medical condition.

What "no consistent harm" actually means here

This is a meaningfully different claim than "hormonal contraceptives are safe for everyone with these conditions." The review's own framing draws a distinction between the general pattern across most studies (no consistent short-term harm) and specific high-risk subgroups where modest adverse metabolic shifts did appear [s1] — the review's summary doesn't specify precisely which subgroups these were, only that they existed within the broader dataset. That distinction is the practical takeaway: broad reassurance for most women with these conditions doesn't rule out individual risk factors mattering for some.

The gaps this review identifies in its own evidence base

The study's authors are explicit about weaknesses in the underlying literature they reviewed: inconsistent reporting of contraceptive dose, formulation, and duration across studies made direct comparison difficult, and the English-language restriction and lack of protocol registration for many included studies are cited as methodological limitations of the review itself [s1]. The uneven coverage of outcome types — glycaemic outcomes reported in under 16% of studies, for instance — means the evidence base for some specific safety questions (like blood-sugar effects, particularly relevant for women with diabetes) is considerably thinner than for others.

What this doesn't establish

A systematic review is only as strong as the studies it pools, and the descriptive (rather than statistically pooled) synthesis here, necessitated by the heterogeneity across the 44 included studies, means this review can characterize a general pattern but can't produce a single quantified risk estimate the way a formal meta-analysis would. Most of the studies reviewed also likely captured relatively short observation windows — the review's own conclusion specifically qualifies its "no consistent harm" finding as applying to short-term outcomes, leaving longer-term cardiometabolic safety in these populations less well characterized.

What the authors recommend

The review's authors call for "risk-stratified use" of hormonal contraceptives in women with these underlying conditions, alongside further standardized longitudinal research to better characterize risk in specific high-risk populations [s1] — a call for more individualized clinical decision-making rather than a blanket policy in either direction.

What to watch

Whether future, better-standardized studies can identify which specific high-risk subgroups carry elevated cardiometabolic risk from hormonal contraceptive use, and whether longer-term outcome data closes the gaps this review identifies. This article is not medical advice; contraceptive choice for women with hypertension, diabetes, or obesity should be discussed with a clinician familiar with individual risk factors.

Sources

1. Cardiometabolic, Glycaemic, and Metabolic Safety of Hormonal Contraceptives in Women with Medical Conditions: A Systematic Review — International Journal of Women's Health, 29 May 2026